What are you looking for?
Heidelberg Engineering announced FDA clearance of the latest version of its SPECTRALIS® software for multimodal retinal imaging. The release introduces a 250 kHz scan speed option for OCT Angiography (OCTA), adding to the existing 85 and 125 kHz settings available through SPECTRALIS with SHIFT Technology. According to the company, the new setting enables faster OCTA... ...
The US Food and Drug Administration (FDA) approved TECNIS PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for...
Ophthalmology 360 spoke with Pravin Dugel, MD, executive chair, CEO, and President of Ocular Therapeutix about the company’s recent announcement about phase...
Topcon Healthcare, Inc announced a commercial partnership with RemoniHealth to expand remote care management and AI-enabled monitoring for ocular disease, in a...
Qlaris Bio, Inc announced positive topline results from two Phase 2 clinical trials evaluating QLS-111 in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). Both trials, Osprey and...
Bausch + Lomb has announced the commercial launch of its enVista Aspire monofocal and toric intraocular lenses (IOLs) in the European Union, following CE Mark approval last year, according to...
Canyon Labs, a global leader in analytical and packaging lab testing for medical devices and pharmaceuticals, has acquired iuvo BioScience’s laboratory services and scientific consulting divisions, according to a press... ...
Bausch + Lomb Corporation announced its acquisition of Elios Vision, Inc., the developer of the ELIOS procedure—the first clinically validated minimally invasive glaucoma surgery (MIGS) technique using an excimer laser....
Harrow has relaunched Triesence, an FDA-approved, preservative-free corticosteroid used in eye surgeries and to treat severe ocular inflammation, according to a company press release. Triesence had been absent from the...
Ocugen, Inc announced the first patient has been dosed in the Phase 3 LIMELIGHT clinical trial for OCU400, a novel gene therapy designed to treat retinitis pigmentosa (RP), a group...
Oculis Holding AG has reported positive topline results from its Phase 2b RELIEF trial evaluating licaminlimab, an anti-TNFα eye drop, for dry eye disease, according to a company press release....
In the dynamic realm of healthcare, innovation often arises from a fusion of necessity and foresight. This ethos finds embodiment in the creation of the American College of Eye Technicians...
